This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n13http://linked.opendata.cz/resource/drugbank/drug/DB04743/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04743/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB04743/identifier/chebi/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04743/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04743/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB04743/identifier/pdb/
n17http://www.drugs.com/international/

Statements

Subject Item
n2:DB04743
rdf:type
n3:Drug
n3:description
Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.
n3:group
withdrawn
n3:halfLife
1.8–4.7 hours
n3:indication
For the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.
owl:sameAs
n6:DB04743 n10:DB04743
dcterms:title
Nimesulide
adms:identifier
n8:Nimesulide n9:PA137179528 n12:DB04743 n13:D01049 n14:44445 n15:NIM
n3:mechanismOfAction
The therapeutic effects of Nimesulide are the result of its complete mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine.
n3:routeOfElimination
Renal (50%), fecal (29%)
n3:toxicity
Oral TDLO (human): 1.429 mg/kg; Oral TDLO (woman): 2 mg/kg; Oral LD50 (rat): 200 mg/kg; Oral LD50 (mouse): 392 mg/kg
n3:proteinBinding
>97.5%
n3:synthesisReference
Bernard Pirotte, Geraldine Piel, Philippe Neven, Isabelle Delneuville, Joszef Geczy, "Water-soluble nimesulide salt and its preparation, aqueous dolution containing it, nimesulide-based combinations and their uses." U.S. Patent US5756546, issued November, 1991.
foaf:page
n17:nimesulide.html
n3:IUPAC-Name
n4:271B4F28-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4F2E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4F2D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4F2A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4F2B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4F2C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4F26-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4F27-363D-11E5-9242-09173F13E4C5 n4:271B4F24-363D-11E5-9242-09173F13E4C5 n4:271B4F3F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4F25-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4F34-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4F35-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4F2F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4F30-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4F32-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4F31-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4F33-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
51803-78-2
n3:category
n3:Bioavailability
n4:271B4F3A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4F3C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4F3D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4F3E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4F39-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4F38-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4F3B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4F29-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4F36-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4F37-363D-11E5-9242-09173F13E4C5